Stephen Dilly, MD, PhD

Dr. Dilly is the CEO of APT Pharmaceuticals. He graduated as a physician from the University of London in 1982 and received his Ph.D. in Cardiac Physiology from University of London in 1988. He began his industry career with Pfizer Central Research in the United Kingdom in 1986 and since then has held positions of increasing responsibility with Beecham, SmithKline Beecham (Vice President of CardioPulmonary, Vice President of Clinical Neuroscience), Genentech (Head of Clinical, Head of Development Sciences) and Chiron BioPharma (Senior Vice President Development, Chief Medical Officer). During his career, he has been closely associated with the development and launch of a number of important new drugs across many therapeutic areas, including Kytril, Paxil CR, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin.